PFCS
URGN icon

Pale Fire Capital SE’s UroGen Pharma URGN Stock Holding History

Pale Fire Capital SE’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,893
Closed -$231K – 74
2025
Q1 		$231K Buy
20,893
+8,393
+67% +$89.5K 0.03% 36
2024
Q4 		$133K Buy
+12,500
New +$150K 0.03% 38

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Pale Fire Capital SE's URGN Position: Q2 2025 in Review

Pale Fire Capital SE sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 20,893 shares — an estimated $231K sold.

Pale Fire Capital SE first reported a position in URGN in Q4 2024 and held it in 2 quarters. The position peaked at $231K in Q1 2025. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

  • Pale Fire Capital SE reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
  • Pale Fire Capital SE sold 20,893 UroGen Pharma shares in Q2 2025, an estimated $231K.
  • Pale Fire Capital SE first reported a position in UroGen Pharma in Q4 2024 and held it in 2 quarters.
  • Pale Fire Capital SE's UroGen Pharma position peaked at $231K in Q1 2025.
  • 150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on Pale Fire Capital SE's 13F filing for Q2 2025, filed 13 Aug 2025.